Involuntary in Medical Technology

VA-NIH Study Offers Hope for Parkinson's Patients

... stiffness. Many were also developing side effects from the drugs, such as involuntary face, arm or leg movements. Researchers followed the patients for ... gained an average of 4.6 hours per day of good motor control and few or no involuntary movements, compared with no gain for those on medical therapy alone; ...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

... site, sleepiness, dizziness, feeling of inner restlessness, and abnormal muscle movements, including tremor (shaking), shuffling, uncontrolled involuntary movements, and abnormal movements of the eyes. This is not a complete list of all possible side effects. Ask your doctor or treatment team if ...

Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry

... between lurasidone and placebo for EPS (assessed using the Simpson-Angus Scale) or symptoms of tardive dyskinesia (assessed using the Abnormal involuntary Movements Scale). There was a modest but significant worsening at endpoint in akathisia symptoms (assessed using the Barnes Akathisia Scale) for ...

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)

... has been released. The most common side effects that occurred with paliperidone were restlessness and extrapyramidal disorder (for example, involuntary movements, tremors and muscle stiffness). Note Regarding Forward-Looking Statements This press release contains "forward-looking ...

Kyowa Hakko Kirin Announces Development Policy for Anti-Parkinson's Disease Drug KW-6002 (Istradefylline)

... is associated with motor complications such as the development of a shortening response to each dose, which is called "wearing-off phenomenon", and involuntary movements. Contact: TETSURO KUGA Public Relations Kyowa Hakko Kirin Co., Ltd. 1-6-1, Ohtemachi, Chiyoda-ku, Tokyo, Japan ...

Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease

... in a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson's disease experiencing motor fluctuations and abnormal involuntary movements (dyskinesias). The trial results were presented today at the company's 2008 R&D Update meeting being hosted for analysts and portfolio ...

New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence

... a significant advance in the treatment of female SUI." SUI, a condition that affects more than 13 million women in the United States, is the involuntary leakage of urine during routine activities that put pressure on the bladder or urethra, such as laughing, sneezing or coughing. It can be an ...

Findings on Bladder-Brain Link May Point to Better Treatments for Problems in Sleep, Attention

... of brain activity, possibly contributing to disrupted sleep and problems with attention. For one in six Americans who have overactive bladder, the involuntary bladder contractions that often trigger more frequent urges to urinate, such mind-body connections may be of more than academic interest. "We often ...

Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease

... qualifying it as an orphan drug indication. It is caused by the death of specific brain cells and is characterized by the gradual development of involuntary muscle movement, progressive deterioration of cognitive processes and memory (dementia) and severe behavioral disturbances. There are currently no ...

Gene Therapy Improves Vision in Patients with Congenital Retinal Disease

... administration. One patient was better able to navigate an obstacle course compared to before the injection. The patients also had less nystagmus, an involuntary movement of the eyes that is common in LCA. In the patient who experienced better vision even in the uninjected eye, the researchers suggest that the ...

New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women

... Cynthia E Neville, PT, BCIA-PMDB, director of Women's Health Rehabilitation at the Rehabilitation Institute of Chicago. Urinary incontinence, or involuntary loss of bladder control, isn't something that just happens to older patients. In fact, the condition affects men and women alike, young and old. More ...

Smokefree Workplace Law Reduces Heart Attacks 59% Among Nonsmokers, New Research Shows

... rather than the general population. It reaffirms the conclusions of the landmark 2006 U.S. Surgeon General's Report, The Health Consequences of involuntary Exposure to Secondhand Smoke Exposure, which states that secondhand smoke exposure may have immediate effects on the cardiovascular systems of ...

New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence

... of life and a reduction in the frequency and severity of incontinence episodes in the majority of women almost 4 years after treatment. SUI is the involuntary leakage of urine associated with laughing, coughing, sneezing and recreational activities. The condition is caused by a variety of factors, most ...

Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting

... posters: -0- 1. Poster P01.090: involuntary Emotional Expression Disorder (IEED) ... that treatment effects with dextromethorphan in involuntary Emotional Expression Disorder (IEED) may be ... lead product candidate for the treatment of involuntary emotional expression disorder (IEED), Zenvia(TM), ...

Study Suggests Invega Helps Patients With Schizophrenia Maintain Symptom Control

... side effects that occurred with INVEGA during the six week placebo-controlled trials were restlessness and extrapyramidal disorder (for example, involuntary movements, tremors and muscle stiffness). One risk of INVEGA is that it may change your heart rhythm. This effect is potentially serious, and ...

Once Daily, Extended-Release Ropinirole Improves Parkinson's Symptoms in Patients not Optimally Controlled With Levodopa

... to the time during which medication is working and providing benefit, and 'on' time without troublesome dyskinesia which refers to 'on' time without involuntary movements interfering with function or causing discomfort, a common problem in Parkinson's disease. REQUIP XL 24-Hour significantly increased both ...

Avanir Pharmaceuticals Announces Positive Results of Phase III Study for Zenvia in Diabetic Neuropathic Pain

... President and CEO of Avanir Pharmaceuticals. "Avanir now has two Phase III Zenvia programs in areas with significant unmet medical need, one in involuntary Emotional Expression Disorder (IEED) and one in diabetic neuropathic pain. We look forward to the continued development of Zenvia for these two ...

Clinical Trial Results Suggest Long-Term Treatment Benefit of Tetrabenazine for Chorea Associated with Huntington's Disease

... involved in abnormal movements such as chorea. Chorea can be a debilitating feature of a number of neurological diseases, characterized by excessive, involuntary and repetitive movements that may flow from one body part to another. The movements may involve the face, limbs or the entire body. HD is one of the ...

AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at Second International Congress on Neuropathic Pain

... and important safety information regarding FazaClo, please visit www.fazaclo.com, AVANIR's lead product candidate for the treatment of involuntary emotional expression disorder (IEED), Zenvia, is the subject of an approvable letter from the FDA. Additionally, AVANIR recently completed a Phase ...

Antipsychotic Iloperidone Results Show Favorable Akathisia Profile

... (7%), received anticholinergic medication to manage intolerable extrapyramidal symptoms (EPS) (such as tremor, slurred speech, restlessness and involuntary muscle movement) during the course of the study. In contrast, 5% of low-dose and 11% of high-dose iloperidone patients received ...

Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia

... aripiprazole 30 mg: 11.8 percent; placebo: 2 percent). No significant differences were found between aripiprazole and placebo on the Abnormal involuntary Movement Scale (AIMS) or Barnes Akathisia Rating Scale (BARS). Significant differences between aripiprazole and placebo were observed from baseline ...

AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain

... and important safety information regarding FazaClo, please visit www.fazaclo.com. AVANIR's lead product candidate for the treatment of involuntary emotional expression disorder (IEED), Zenvia, is the subject of an approvable letter from the FDA. Additionally, AVANIR recently completed a Phase ...